A total of 206 Private Equity/Venture Financing deals (pending and completed) were announced in the Pharmaceuticals of China, in the last twelve months resulting in a total deal value of over $11,164.3 million. In the LTM period, August 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $2,340.6 million, resulting in an average deal value of $86.7 million during that month. On the other hand, the month of January 2022 was the most prolific in terms of deal volume, recording a total of 27 deals, resulting in an average deal value of $35.5 million during that month.
Of the 206 deals, the deal secured between FountainVest Partners and Beijing Zhendong Langdi Pharmaceutical Co Ltd, was the largest Private Equity/Venture Financing deal in the China Pharmaceuticals sector, which was valued at $900.0 million and was completed on November 19, 2021. The second-largest deal was between 5Y Capital; AIHC Capital Management Limited; Alwin Capital; BioTrack Capital; Boyu Capital Consultancy Co. Ltd; CTS Capital Advisors LLC; Firstred Capital; Gaorong Capital; GL Ventures; HighLight Capital (China); Invesco Developing Markets Fund; Kaiser Permanente Ventures; Legend Capital Co Ltd; Lilly Asia ventures; Loyal Valley Capital; MSA Capital; Octagon Capital Group LLC; Oriental Spring; PICC Capital Equity Investment Co Ltd; Qiming Venture Partners; Temasek Holdings (Private) Ltd; Tiger Jade Capital LLP; Winfast Holding; Yingke PE; Youshan Capital; Yunfeng Capital and Suzhou Abogen Biosciences Co Ltd, while the third-largest deal was between Aobo Capital and Jingtai Technology. The 5Y Capital; AIHC Capital Management Limited; Alwin Capital; BioTrack Capital; Boyu Capital Consultancy Co. Ltd; CTS Capital Advisors LLC; Firstred Capital; Gaorong Capital; GL Ventures; HighLight Capital (China); Invesco Developing Markets Fund; Kaiser Permanente Ventures; Legend Capital Co Ltd; Lilly Asia ventures; Loyal Valley Capital; MSA Capital; Octagon Capital Group LLC; Oriental Spring; PICC Capital Equity Investment Co Ltd; Qiming Venture Partners; Temasek Holdings (Private) Ltd; Tiger Jade Capital LLP; Winfast Holding; Yingke PE; Youshan Capital; Yunfeng Capital-Suzhou Abogen Biosciences Co Ltd deal and the Aobo Capital-Jingtai Technology deal were valued at $700.0 million and $400.0 million, respectively. The fourth-largest deal was between Hillhouse Capital Group-Shanghai Asymchem Biotechnology Development valued at $392.6 million, whereas the deal between 5Y Capital; Chimera Investment LLC; China Fortune Ocean; DNE Capital Ltd; IMO Ventures, Inc.; JinYi Capital; Mirae Asset Financial Group; New Frontier Group; SoftBank Vision Fund LP-Suzhou Abogen Biosciences Co Ltd valued at $300.0 million was the fifth-largest deal.
Cumulatively, the top five deals amounted to $2,692.6 million and accounted for nearly 24.12% of the total deals (by value) announced during the last twelve months.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward